Healthcare Triage: Gaming the System – Orphan Drugs Part 3

Healthcare Triage: Gaming the System – Orphan Drugs Part 3

Image result for Healthcare Triage: Gaming the System – Orphan Drugs Part 3

Even if the Orphan Drug Act were working properly, its enormous costs might outweigh its exiguous benefits. But it’s not working properly. Drug manufacturers are gaming the Act in at least three important ways. They’re the topic of this week’s Healthcare Triage.

Prescription drug spending surges amid market forces

http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/prescription-drug-spending-surges-amid-market-forces?cfcache=true

 

AHA furious over ruling to exclude ‘orphan’ drugs from 340B program

http://www.healthcarefinancenews.com/news/aha-furious-over-ruling-exclude-orphan-drugs-340b-program?mkt_tok=3RkMMJWWfF9wsRovu6%2FMZKXonjHpfsX57u4rUa6zlMI%2F0ER3fOvrPUfGjI4IRMFgI%2BSLDwEYGJlv6SgFQ7LHMbpszbgPUhM%3D

The ruling means pharmaceutical companies that make orphan drugs do not have to sell then to rural and cancer hospitals at a discount.